Thomas Yorkey - Procept Biorobotics VP RD
| PRCT Stock | USD 95.59 1.70 1.75% |
Insider
Thomas Yorkey is VP RD of Procept Biorobotics Corp
| Age | 62 |
| Address | 150 Baytech Drive, San Jose, CA, United States, 95134 |
| Phone | 650 232 7200 |
| Web | https://www.procept-biorobotics.com |
Procept Biorobotics Management Efficiency
The company has return on total asset (ROA) of (0.1673) % which means that it has lost $0.1673 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3702) %, meaning that it created substantial loss on money invested by shareholders. Procept Biorobotics' management efficiency ratios could be used to measure how well Procept Biorobotics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.28 in 2024. Return On Capital Employed is likely to drop to -0.32 in 2024. At this time, Procept Biorobotics' Non Current Liabilities Total is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 7 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 26.1 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Sri Radhakrishnan | Pulmonx Corp | N/A | |
| John McKune | Pulmonx Corp | 48 | |
| Rajbir Denhoy | Establishment Labs Holdings | 53 | |
| Mark Saxton | Neuropace | 59 | |
| Michael Hutchinson | LivaNova PLC | 53 | |
| Elizabeth Giddens | Integer Holdings Corp | 49 | |
| Daniel Owens | Treace Medical Concepts | 52 | |
| Michael Favet | Neuropace | 54 | |
| Ehab Esmail | Orthofix Medical | 52 | |
| Geoffrey Rose | Pulmonx Corp | 50 | |
| McAlister Marshall | Integer Holdings Corp | 51 | |
| Jason Edie | Paragon 28 | N/A | |
| MBA BS | Sight Sciences | N/A | |
| Laverne Council | CONMED | 59 | |
| Paul Badawi | Sight Sciences | 49 | |
| Mark Quick | Orthofix Medical | N/A | |
| Bradley JD | Axogen Inc | 54 | |
| Jesse Selnick | Sight Sciences | N/A | |
| Andre Marquette | Neuropace | N/A | |
| Salvador Dada | Establishment Labs Holdings | 42 | |
| Lindsey Little | LivaNova PLC | N/A | |
Management Performance
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.17 |
Procept Biorobotics Corp Leadership Team
Elected by the shareholders, the Procept Biorobotics' board of directors comprises two types of representatives: Procept Biorobotics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Procept. The board's role is to monitor Procept Biorobotics' management team and ensure that shareholders' interests are well served. Procept Biorobotics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Procept Biorobotics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthew CFA, Vice Relations | ||
| Hisham Shiblaq, Executive Officer | ||
| Stacey Porter, Chief Officer | ||
| Minni Vittal, VP Officer | ||
| Reza Zadno, CEO President | ||
| Kevin Waters, Executive CFO | ||
| Alaleh Nouri, Chief EVP | ||
| Mohan Sancheti, Senior Operations | ||
| Thomas Yorkey, VP RD | ||
| Bijesh Chandran, Senior Assurance | ||
| Barry Templin, Executive Development |
Procept Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Procept Biorobotics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (0.50) % | ||||
| Operating Margin | (0.38) % | ||||
| Current Valuation | 5.06 B | ||||
| Shares Outstanding | 54.11 M | ||||
| Shares Owned By Insiders | 4.60 % | ||||
| Shares Owned By Institutions | 86.33 % | ||||
| Number Of Shares Shorted | 6.37 M | ||||
| Price To Book | 21.44 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Procept Stock Analysis
When running Procept Biorobotics' price analysis, check to measure Procept Biorobotics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Procept Biorobotics is operating at the current time. Most of Procept Biorobotics' value examination focuses on studying past and present price action to predict the probability of Procept Biorobotics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Procept Biorobotics' price. Additionally, you may evaluate how the addition of Procept Biorobotics to your portfolios can decrease your overall portfolio volatility.